Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards

Glaxo Undeterred by Human Genome ‘Poison Pill’

By Pharmaceutical Processing | May 18, 2012

LONDON (AP) — GlaxoSmithKline says it will persist with its bid to take over U.S. company Human Genome Sciences despite the target’s new ‘poison pill’ defense.

In a statement issued after the market closed on Thursday, GSK said it believes its $13 per share offer represents full value for HGS, its partner in developing new drug treatments.

Rockville, Maryland-based HGS on Thursday announced its defensive move, which will dilute holdings if anyone attempts to acquire 15 percent or more of its stock without board approval.

GSK’s offer closes on June 7.

GSK and Human Genome Sciences split sales of the injectable biotech drug Benlysta, which last year became the first new drug approved for lupus in 50 years. Sales so far have fallen short of expectations, with monthly revenue averaging $11 million, but some analysts believe the drug could grow into a billion-dollar blockbuster.

HGS said Thursday that Glaxo’s offer failed to capture the “significant upside potential” represented by Benlysta and the company’s pipeline of drugs including darapladib, for treatment of cardiovascular disease, and albiglutide, for type 2 diabetes.

GSK said it believes the earliest the first Phase III trial for darapladib can finish is in 2013 and the earliest the second trial can finish is sometime in 2014.

GlaxoSmithKline said it owns “the vast majority of the economics” associated with albiglutide and darapladib.

“HGS is entitled to certain conditional milestones and a mid-single-digit royalty if albiglutide is successfully commercialized. For darapladib, if successfully developed, HGS is entitled to a 10 percent royalty and an option to co-promote and receive up to 20 percent profit share but will also need to make a proportionate contribution to investment for costs of launch and promotion,” GSK said.

 

 

Related Articles Read More >

A Zipline fixed-wing drone in the air drops a package
Cardinal Health starts Zipline drone deliveries of drugs and medical supplies
Pfizer logo
Pfizer to spend $120M to make COVID-19 oral treatment in U.S.
Image of MedTrace Pharma's P3 automated delivery system for 15-O water in action
MedTrace Pharma moves forward on 15 O-water imaging tech
coronavirus COVID-19 Pfizer
NIH starts evaluating second COVID-19 booster shots in adults

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Pharmaceutical Processing news in a minute?

We Deliver!
Pharmaceutical Processing Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Pharmaceutical Processing World
  • Subscribe to Our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards